Topic: Cancer Immunotherapy

Download All Articles

A special issue of Journal of Cancer Metastasis and Treatment  (Print ISSN:2394-4722; Online ISSN:2454-2857).

Deadline for manuscript submissions: 2 Oct 2017

Share This Special Issue

Guest Editor(s)

  • Shuen-Kuei Liao, PhD
    The PhD Program for Cancer Biology and Drug Discovery, Taipei Medical University, Taipei 110, Taiwan, China.

    Website | E-mail

Special Issue Introduction:

This special issue covering seven articles in the area of cancer Immunotherapy/biotherapy provides useful source information as well as a landmark at an extremely exciting time in the development of many innovative immune/biological agents, such as non-specific immunomodulators, immune checkpoint molecules, humanized antibodies, genetically modified T cells and neoantigen/RNA mutanome vaccines. The invited authors have covered the scientific principles, technologies, experimental models, clinical approaches and future directions in their own ways. We do not intend to remove areas of overlapping among articles particularly the review articles, so that a variety of perspectives could be presented on the different approaches to the many laboratory and clinical problems. Just as important, strategies with individualized and combinational (with any standard treatment) approaches for greater efficacies have been much emphasized in this type of treatment modality. While currently only small proportions of patients with selected cancer types refractory to the standard therapies have benefitted, some major scientific, clinical and regulatory hurdles still need to be overcome in order to bring the full potential clinical benefits in years to come. I sincerely hope that this special issue will give our readers a snapshot of this exciting and evolving new field.


Cancer immunology and immunotherapy, hyperthermia, uveal melanoma, hepatocellular catcinoma, liver microenvironment, immune checkpoint inhibitors, chimeric antibodies, NK cells, dendritic cells, cytotoxic T-lymphocytes, CAR-T cells, neoantigen/RNA mutanome vaccines, metastasis, cancer stem cells, combinational therapy

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 2 Oct 2017
Contacts: Carrie Wang, Managing Editor,

Published Articles Download All Articles
  • Immunotherapy of cancer is a part of biotherapy

    Shuen-Kuei Liao , Robert K. Oldham
    This article belongs to the Special Issue Cancer Immunotherapy
    J Cancer Metastasis Treat 2018;4:3. | doi:10.20517/2394-4722.2017.63
    Published on: 22 Jan 2018  | Viewed:1333  | Downloaded:170
    +HTML| PDF
  • A primer on recent developments in cancer immunotherapy, with a focus on neoantigen vaccines

    Taku A. Tokuyasu , Jian-Dong Huang
    Cancer immunotherapy has now been conclusively shown to be capable of producing durable responses for a substantial number of patients. Adoptive cell transfer and checkpoint blockade therapies in particular both demonstrate that antigen-specific immune responses can be dramatically effective, even in previously refractory late stage disease. Such developments, together with advances in... Read more
    This article belongs to the Special Issue Cancer Immunotherapy
    J Cancer Metastasis Treat 2018;4:2. | doi:10.20517/2394-4722.2017.52
    Published on: 18 Jan 2018  | Viewed:5783  | Downloaded:371
    +HTML| PDF
  • Introduction to the Special Issue on Cancer Immunotherapy

    Shuen-Kuei Liao
    J Cancer Metastasis Treat 2017;3:217. | doi:10.20517/2394-4722.2017.21
    Published on: 31 Oct 2017  | Viewed:865  | Downloaded:115
    +HTML| PDF
  • Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery

    Yohsuke Yagawa , Keishi Tanigawa , Yasunobu Kobayashi , Masakazu Yamamoto
    Hyperthermia is a type of medical modality for cancer treatment using the biological effect of artificially induced heat. Even though the intrinsic effects of elevated body temperature in cancer tissues are poorly understood, increasing the temperature of the body has been recognized as a popular therapeutic method for tumorous lesions as well as infectious diseases since ancient times.... Read more
    J Cancer Metastasis Treat 2017;3:218-30. | doi:10.20517/2394-4722.2017.35
    Published on: 31 Oct 2017  | Viewed:3406  | Downloaded:316
    +HTML| PDF
  • Immunological aspect of the liver and metastatic uveal melanoma

    Mizue Terai , Michael J. Mastrangleo , Takami Sato
    Uveal (eye) melanoma is the most common primary eye malignancy in adults. Despite optimal treatments for primary uveal melanoma, up to 50% of patients subsequently develop systemic metastasis, often in the liver. Once hepatic metastasis develops, the survival of patients is generally short and currently available treatments fail to show meaningful improvement of survival. Recent development of... Read more
    J Cancer Metastasis Treat 2017;3:231-43. | doi:10.20517/2394-4722.2017.39
    Published on: 31 Oct 2017  | Viewed:2995  | Downloaded:192
    +HTML| PDF
  • Cell-mediated immunotherapy for hepatocellular carcinoma

    Wei-Chen Lee
    Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Most of the time, these tumors are diagnosed at late stages. Because no effective treatments exist for patients with advanced stage HCC, there is an urgent need for novel, effective treatments. Cancer cells originate as a consequence of abnormal expression of oncogenes or loss of tumor suppressor genes. Often, neoplastic... Read more
    J Cancer Metastasis Treat 2017;3:244-9. | doi:10.20517/2394-4722.2017.48
    Published on: 31 Oct 2017  | Viewed:1716  | Downloaded:156
    +HTML| PDF
  • Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead

    Stanley J. Oiseth , Mohamed S. Aziz
    The knowledge that the body possesses natural defenses to combat cancer existed long before the modern period, with multiple anecdotal reports of tumors miraculously disappearing, sometimes spontaneously or after a febrile or infectious episode. Spontaneous tumor regression of untreated malignant tumors is currently a well-accepted albeit rare phenomenon, and it is recognized that... Read more
    J Cancer Metastasis Treat 2017;3:250-61. | doi:10.20517/2394-4722.2017.41
    Published on: 31 Oct 2017  | Viewed:34881  | Downloaded:3978
    +HTML| PDF
  • Systemic humoral responses of non-muscle-invasive bladder cancer during BCG treatment: less is more

    Fernando M. Calais da Silva , Paula A. Videira , Dário Ligeiro , Maria Guadalupe Cabral , Richard Sylvester , Fernando E. Calais da Silva , Hélder Trindade
    Aim: Intravesical Bacille Calmette-Guérin (BCG) is the mainstay adjuvant treatment of non-muscle-invasive bladder cancer. However, one third of the patients on BCG regimen relapse within the first year of treatment. This study aimed at identifying biomarkers to predict response to BCG treatment. Methods: Gene expression was analyzed in blood cells of 58 patients treated with BCG through six... Read more
    J Cancer Metastasis Treat 2017;3:116-26. | doi:10.20517/2394-4722.2017.25
    Published on: 14 Jul 2017  | Viewed:2162  | Downloaded:128
    +HTML| PDF
Journal of Cancer Metastasis and Treatment ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.